The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - Amgen; Guardant Health
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai
 
David Z. Chang
No Relationships to Disclose
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Fusion Pharmaceuticals (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); Bellicum Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); Hutchison MediPharma (Inst); IGM (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo/Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); NeoImmuneTech (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Novocure (Inst); Numab (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Treadwell Therapeutics (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical
 
Timothy Larson
No Relationships to Disclose
 
Allen Lee Cohn
Honoraria - Amgen
Expert Testimony - Department of Justice
 
Timothy K. Huyck
No Relationships to Disclose
 
David Cosgrove
Employment - Biocompatibles; Compass Oncology
Leadership - US Oncology
Consulting or Advisory Role - Biocompatibles
Speakers' Bureau - Biocompatibles
Travel, Accommodations, Expenses - US Oncology
 
Joseph A. Fiorillo
No Relationships to Disclose
 
Lawrence E. Garbo
Stock and Other Ownership Interests - Abbott; Abbvie; Merck; Pfizer
Research Funding - Acerta Pharma; ACT Biotech; Agendia; Alira Health; Amgen; Astellas Pharma; AstraZeneca; AVEO; Bayer; Biodesix; Biomarin; Blueprint Medicines; Boston Biomedical; Bristol-Myers Squibb; Calithera Biosciences; Celgene; Chiltern; Clovis Oncology; Corvus Pharmaceuticals; Eisai; EMD Serono; Epizyme; Fox Chase Cancer Center; Galera Therapeutics; Genentech; GlaxoSmithKline; GRAIL; Heat Biologics; Immunomedics; Incyte; Janssen; Juno Therapeutics; Lilly; Medivation; Mirati Therapeutics; Myriad Genetics; Novartis; Novella Clinical; NSABP Foundation; Odonate Therapeutics; Pfizer; Precision Oncology; Radius Health; Roche; Roche; Seagen; Senhwa Biosciences; Syndax; Takeda; Tyme
 
Shruthi Ravimohan
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Von Potter
Employment - Forma Therapeutics
 
David D'Adamo
Employment - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Eisai
Other Relationship - Eisai
 
Neelesh Sharma
Employment - Bayer; Novartis
Stock and Other Ownership Interests - Adaptimmune; Autolus; AVEO; Exelixis; Galectin Therapeutics; GalMed Pharmacueticals; IMMUNE PHARMACEUTICALS; IMMUNOCELLULAR THERAPEUTICS; INTERCEPT PHARMACEUTICALS; Regeneron; Rockwell Medical; Spectrum Pharmaceuticals; Titan Pharmaceuticals
 
Ying A. Wang
Employment - Bayer
Stock and Other Ownership Interests - Bayer; Forma Therapeutics (I); Novartis
 
Sabine Coppieters
Employment - Bayer
Stock and Other Ownership Interests - Bayer
 
Matthias Herpers
Employment - ClinStat
 
Carolina Soares Viana de Oliveira
Employment - Bayer
 
Andrew Scott Paulson
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Aptose Biosciences
Honoraria - Cardinal Health
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bristol Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Pfizer
Research Funding - AstraZeneca (Inst); bristol myers squibb (Inst); Deciphera (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Hutchison MediPharma (Inst); incyte (Inst); Ipsen (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)